Byondis and Medac link up to commercialise trastuzumab duocarmazine
Byondis and Medac have entered into a license and collaboration agreement for form of targeted chemotherapy
Read More
Tag: Medac
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
